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ABSTRACT
Objective: The objective of this research is to evaluate the effect of benzylideneacetone analog of curcumin against Mycobacterium tuberculosis (MTB) 
H37Rv.
Method: The activity of benzylideneacetone analog of curcumin is evaluated using mycobacteria growth indicator tube (MGIT) method and microplate 
alamar blue assay (MABA) method. The compound of minimum inhibitory concentration (MIC) is defined as the minimum concentration of drugs 
which really inhibit the growth of MTB.
Result: The MIC compound of 1,5-bis(3,4-dichlorophenyl)-1,4-pentadiene-3-one (C9) and 1,5-bis(3-chlorophenyl)-1,4-pentadiene-3-one (C10) can 
inhibit the bacteria of MTB at the concentration of 500 μg/ml using MGIT method. Based on MABA method, it can be obtained similar MIC value of C9 
compound and C10 compound that are 187.5 μg/ml.
Conclusion: C9 and C10 have antituberculosis activity. Benzylideneacetone analog of curcumin which has chlor moiety has a better activity in 
inhibiting MTB, but it still needs further research to make it become a potent antituberculosis drug.
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INTRODUCTION
Tuberculosis (TB) is one of the infectious diseases which are caused 
by MTB and it happens in most of developing countries in the world. 
In 2015, based on the World Health Organization, the case of TB in the 
world was about 10.4 million on the new TB case. 5.9 million (56%) in 
men and 3.5 million (34%) in women. Whereas, HIV patients with new 
TB case were only 1.2 million (11%) [1]. The most identified countries 
of 60% of new TB case were India, Indonesia, China, Nigeria, Pakistan, 
and South Africa [1].
TB case is still being a big burden in Indonesia since the TB case amount 
is always increasing with the incident rate was about 300.000 in 2014. 
TB patients should obey the TB treatment to get an effective treatment 
and to avoid the existence of anti-TB drugs resistance. The failure of 
treatment can cause resistance of drugs which is usually known as 
multidrug resistance (MDR-TB) and extensively drug resistance (XDR-
TB). MDR-TB infected patients who were resistant against the first line 
of TB drugs such as isoniazid and rifampicin, while XDR-TB happened 
when the bacteria were resistant against the first line and the second 
line of TB drugs such as the group of fluoroquinolones [2].
Turmeric is known as traditional ingredient and it is used as traditional 
medicine or traditional drinks. The yellow pigment of Curcuma longa was 
known as curcuminoid which was found as active substance in curcuma 
rhizome [3]. Curcuminoid consists of curcumin, dimetoxycurcumin, and 
bis-dimethoxycurcumin which are found in the rhizome of turmeric and 
it is widely used in traditional medicine [4,5]. Curcumin has an activity 
of antioxidant and anti-inflammation [6,7], antidiabetic [8], antivirus 
[9,10], antiallergy [11], antihyperlipidemic [12], anti-infective [13], 
anticancer [14], and antibacteria against Escherichia coli, Bacillus subtilis, 
Helicobacter pylori, and MTB [15,16]. Curcumin was reported as non-toxic 
compound against mice, rabbits, monkeys, and human volunteers [17].
Curcumin had been reported as potent anti-TB drugs even though the 
mechanism of anti-TB was certainly not known yet [16]. The previous 
studies showed that curcumin could inhibit inflammation, oxidation, 
and it could induce apoptosis, and it also could inhibit the expression of 
gene and the function of toll-like receptor 2 which might occur through 
oxidation process. It indicated the ability of curcumin which had a role 
in macrophage apoptosis which was caused by MTB [16,18]. Hence, the 
objective of this research is to know the antimycobacterium activity in 
benzylideneacetone analog of curcumin.
MATERIALS AND METHODS
Materials
The benzyliene-acetone analogues of curcumin were obtained from 
Curcumin Research Center (CRC) Faculty of Pharmacy, Universitas 
Gadjah Mada. Dimethyl sulfoxide (DMSO) (Sigma Aldrich), Middlebrook 
7H9 broth (Difco Laboratories), Oleic acid/Albumin/Dextrose/Catalase 
enrichment (OADC) (Becton Dickinson and Company), Polymyxin B, 
Amphotericin B, Nalidixic acid, Trimetroprim, and Azlocillin (PANTA) 
(Becton Dickinson and Company), Tween 80 (Sigma Aldrich), Alamar 
Blue Reagent (Sigma Aldrich), Isoniazid (Sigma Aldrich), Rifampicin 
(Sigma Aldrich), Kit mycobacteria growth indicator tube (MGIT) (Becton 
Dickinson and Company), Mycobacterium tuberculosis H37Rv from 
Mirobiology Laboratory, Faculty of Medicine, Universitas Gadjah Mada.
Preparation of MTB
MTB H37Rv was grown in Middlebrook 7H9 broth supplemented with 
10% OADC and 0.05% (v/v) Tween 80 to the log phase at 37°C for 
4–5 weeks on shaking incubation of 120 r/min.
Preparation sample and drug of TB
The first-line therapy for TB drug is isoniazid and rifampicin. Isoniazid 
and rifampicin were dissolved in water and dimethylsulfoxide 1% with 
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concentration of 10 µg/mL, respectively. Then, they were filtered using 
0.45 μm membrane syringe filter before use and stored at −80°C deep-
freezer until use. Sample was dissolved in dimethylsulfoxide 1% with 
concentration of 1000, 750, 500, 375, 250, 187.5, and 125 µg/ml.
Drug susceptibility testing of MTB
It is used to determine the ability of compound curcumin analogs to 
inhibit MTB using the kit MGIT BD Biosciences. MGIT tube contains the 
growth medium. 500 μL of OADC and 1000 μL of PANTA were added to 
each MGIT tube. Next, 1000 μL of drug or sample solution with various 
concentrations was added to the MGIT tube. Then, 1000 μL bacterial 
suspension in medium Middlebrook 7H9 was added and incubated at a 
temperature 370°C for 2 days. The bacterial cells were adjusted accord 
McFarland standard. The MGIT tubes were bar scanned and transferred 
to the Bactec 960 system for 14 days. The growth of MTB detected in 
these instruments (Bactec 960 System). The instrument monitors the 
entered susceptibility test set. Once the test is complete (14 days), 
the instrument will indicate that the results are ready. The results are 
qualitative such as susceptible (S), resistant (R), or indeterminate (X). 
The instrument interprets results at the time when the growth unit 
(GU) in growth control reaches 400. At this point, the GU values of the 
drug vial are evaluated. Susceptible when the GU of the drug tube is 
<1000 and resistant when the GU of the drug tube is 1000 or more. 
Further, X results when certain conditions occur which may affect the 
test, such as GU of the control reaches >400 in <4 days.
Microplate alamar blue assay (MABA)
This test was used alamar blue reagents and performed 96-well 
microplates. The wells on 96-well microplates are illustrated with rows 
A-H and columns 1-12. The outer wells are the lines A1 - H1, A12 - H12, 
A1 - H12, and H1 - H12 filled with 200 μL sterile water. 100 µL of 7H9GC 
media was added to all experimental wells (in addition to the outer 
wells). 200 µL of the sample solution was added to the well on line B in 
columns 2, 3, 4, and 5 (B2, B3, B4, and B5). Using a micropipette, 100 μL 
was transplanted to line C and homogenized then from line C of 100 μL 
transplanted to line D. The dilution system was continued until line G. 
Line B6-G6 was administered 100 μL isoniazid 10 μg/mL and line B7-G7 
was administered 100μL rifampicin 10 μg/mL, both compounds were 
used as positive controls. Line B8-G8 was used as a controlled solvent 
which was administered as 100 μL DMSO 1% and administered 100 μL 
of bacteria in line B9-G10 used as a sample free control (inoculum). 
Suspension of MTB (100 μL) is added to the test well. The plates were 
sealed with parafilm and incubated at 37°C for 5 days. On the 6th day 
after incubation, 50 μL alamar blue reagent (1:1 mixture of alamar blue 
and 10% Tween 8) was added to B11 and incubation for 24 h. Observed 
the change color in B11 which when turned into pink then the alamar 
blue reagent is added to the all well test but if B11 remains blue, so 
apply the reagent on B12 (and same treatment as B11) incubation for 
an additional 24 h at 37°C, and color change recorded. Pink color is 
interpreted as the ability of compounds in inhibiting bacteria minimum 
inhibitory concentration (MIC) and blue color is a described of the 
growth of bacteria and inactive compounds in bacterial inhibition.
RESULTS
Antituberculosis susceptibility using MGIT
The ability of curcumin analogs inhibits the growth of MTB determined 
MGIT test. The result is described in Table 1. Based on data, it has 
been shown that the curcumin analogs C9 and C10 have significant 
TB activities when they are compared to isoniazid and rifampicin. The 
susceptibility of MTB test results showed that H37Rv strain is sensitive 
to isoniazid and rifampicin.
Inhibition MTB with MABA
The MIC of antituberculosis assay of curcumin analogues against MTB 
H37Rv are shown in Table 2. The results showed that C9, and C10 
inhibited MTB H37Rv with MIC 187.5 μg/mL. Isoniazid and rifampicin 
were used as positive control in determining MIC of curcumin analogues.
DISCUSSION
TB is the main cause of morbidity and mortality against one-third of 
population in the world. The failure of treatment is often occurred in 
this transmitted disease, especially in developing countries, so it can 
cause human health problems. MDR-TB and XDR-TB can increase the 
serious threat against human health which is caused by the failure of TB 
treatment and impracticality TB treatment. The treatment regimen for 
TB consists of four drugs with different mechanism of treatment. Most 
of new generations of drugs are developed on clinical therapy, so we 
need the new drugs candidate that has different mechanism and new 
target. Therefore, new drugs are needed to shorten the duration of TB 
treatment in both of new TB case and MDR-TB case to minimize the 
infection and mortality.
Curcumin has many beneficial pharmacological activities, but the 
instability of the compound can be a serious problem. The stability 
of curcumin is affected by sunlight ray and pH of the compound. The 
increasing of pH more than 7 can cause curcumin decomposition 
and it becomes curcumin decomposition products. They are 
feruloylmethane and ferulic acid from the condensation of retroaldol 
to vanillin and acetone at a rapid tempo. Then, the curcumin 
decomposition caused by sunlight ray also produced ferulic aldehid, 
ferulic acid, products from dihydroxynaphthalene, 4-vinylguaiacol, 
vanillin, and vanillic acid [11]. The active part of methylene is one of 
the factors of the instability of curcumin (Fig. 1). The modification 
of the structure is made to overcome the problem of the compound 
instability by substituting other compounds such as 1,4-pentadiene-
3-one, cyclopentanone, and cyclohexanone in the middle part of 
curcumin (Fig. 2) structure [18].
Table 1: Antituberculosis activity results of curcumin analogs using MGIT method
No Code Concentration (µg/ml)
1000 750 500 375 250 187.5 125
1 C0 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
2 C1 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
3 C2 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
4 C3 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
5 C4 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
6 C5 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
7 C6 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
8 C7 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
9 C9 Sensitive Sensitive Sensitive Resisten Resisten Resisten Resisten
10 C10 Sensitive Sensitive Sensitive Resisten Resisten Resisten Resisten
11 C11 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
12 C15 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
13 C16 Resisten Resisten Resisten Resisten Resisten Resisten Resisten
14 Isoniazid 10 μg/Ml Sensitive
15 Rifampicin 10 μg/Ml Sensitive
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In addition, the modification can also increase the stability of 
curcumin which can obtain better stability (Table 3), more potent 
and secure activity. Some curcumin analog compound was reported 
that they had better pharmacological effect as antioxidant, anti-
inflammation, and antibacteria. They were pentagamavunon-1 
(PGV-1) and PGV-2 [19]. PGV-0 was also a result from modification 
of monoketone curcumin structure which had an activity as anti-
inflammation, anticancer, and antioxidant [20,21], but it still 
had bioavailability problem like what curcumin had [22]. GVT-
0, especially for lower dosage (10 mg/kg), showed the action of 
hepatoprotective on mice as the model [23]. Tetrahydrocurcumin 
was the main metabolism of curcumin which had 3 times better 
activity as antioxidant than curcumin in vitro [24]. Other compounds 
which are resulted from the modification of curcumin structure are 
benzylideneacetone analogs of curcumin. Modification of structure 
was done in the middle part of curcumin by substituting aliphatic 
β-diketone part to acetone. The compound of benzylideneacetone 
analog of curcumin has better activity as antibacteria against 
Streptococcus pneumoniae which can cause respiratory tract 
infection.
The activity of antimycobacterial from benzylideneacetone analog of 
curcumin is evaluated using MGIT method and MABA method. The 
concentrations of benzylideneacetone analog of curcumin which are 
used here are 1000, 750, 500, 375, 250, 187, 5, and 125 μg/mL and 
the positive control group used here is the first-line anti-TB drugs, 
i.e. isoniazid and rifampicin (10 μg/mL).
The result shows that 1,5-bis(3,4-dichlorophenyl)-1,4-pentadiene-3-
one (C9) and 1,5-bis (3-chlorophenyl)-1,4-pentadiene-3-one (C10) are 
the compounds which are the better inhibitor against the growth of 
MTB than other compounds in benzylideneacetone analog of curcumin 
using both MGIT method and MABA method. C9 and C10 compounds 
have lower MIC value than other compounds. These two compounds 
contain chlor moiety at para position. C9 has two chlor moieties both 
at para and at ortho position with hydrogen moiety inside the phenyl 
ring, while C10 has only one chlor moiety inside the phenyl ring and it 
has two hydrogen moieties. It shows that C9 has more halogen moiety 
as the electron withdrawing group. Hence, C9 is more active than C10 
compound. Meanwhile, C16 compound which has two chlor moieties 
and one hydroxyl moiety at ortho position does not have inhibitory 
activity against MTB. Besides, C3 compound which has chlor moiety 
at ortho position and which is in the middle of two hydrogen moieties 
does not show inhibitory activity too against the growth of bacteria. It 
shows clearly that the existence of moiety as the electron withdrawing 
group and the position of the moiety as the electron withdrawing group 
have an important role here.
The position of chlor moiety at para and ortho position has stronger 
activity of anti-TB than those at para and meta position. Hence, the MIC 
value on C9 compound becomes lower than C10 and C16 compound. 
C9 and C10 compound are the most potent compounds in inhibiting 
MTB. The previous studies stated that the existence of electron 
withdrawing group could increase the activity of anti-TB efficiently. 
According to QSAR studies, it was stated that 2-chlor-, 3-chlor-, 
4-methyl-, and 2-chlor-5-substituent could increase the activity of TB 
[23]. The existence of electron withdrawing group such as pyridine, 
nitro, and chlor inside the phenyl ring can also produce strong activity 
of antimycobacterium. Meanwhile, the electron-donating group, such 
as hydroxyl, methoxy, and amino, shows weaker activity. Then, based 
Table 2: MICs of curcumin analogs against MTB H37Rv
No Code Concentration (µg/ml)
1000 750 500 375 250 187.5 125
1 C0 Not active Not active Not active Not active Not active Not active Not active
2 C1 Not active Not active Not active Not active Not active Not active Not active
3 C2 Not active Not active Not active Not active Not active Not active Not active
4 C3 Not active Not active Not active Not active Not active Not active Not active
5 C4 Not active Not active Not active Not active Not active Not active Not active
6 C5 Not active Not active Not active Not active Not active Not active Not active
7 C6 Not active Not active Not active Not active Not active Not active Not active
8 C7 Not active Not active Not active Not active Not active Not active Not active
9 C9 Active Active Active Not active Not active Not active Not active
10 C10 Active Active Active Not active Not active Not active Not active
11 C11 Not active Not active Not active Not active Not active Not active Not active
12 C15 Not active Not active Not active Not active Not active Not active Not active
13 C16 Not active Not active Not active Not active Not active Not active Not active
14 Isoniazid 10μg/Ml Active
15 Rifampicin 10μg/Ml Active
Table 3: Structure and chemical name of 1,5‑diphenyl‑1,4‑pentadiene‑3‑one (Series C) analogs of curcumin
No. R1 R2 R3 Chemical name Code 
1 H OH H 1,5-bis (4-hydroxyphenyl)-1,4-pentadiene-3-one C0
2 OCH3 OH H 1,5-bis (4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one C1
3 H H H 1,5-diphenyl-1,4-pentadiene-3-one C2
4 H Cl H 1,5-bis-(p-chlorophenyl)-1,4-pentadiene-3-one C3
5 H OCH3 H 1,5-bis (4-methoxyphenyl)-1,4-pentadiene-3-one C4
6 H CH3 H 1,5-bis (4-methylphenyl)-1,4-pentadiene-3-one C5
7 H t-C4H9 H 1,5-bis (4-tert-butylphenyl)-1,4-pentadiene-3-one C6
8 H CF3 H 1,5-bis (4-trifluoromethylphenyl)-1,4-pentadiene-3-one C7
9 H N (CH3)2 H 1,5-bis (4-dimethylphenyl)-1,4-pentadiene-3-one C8
10 Cl Cl H 1,5-bis (3,4-dichlorophenyl)-1,4-pentadiene-3-one C9
11 Cl H H 1,5-bis (3-chlorophenyl)-1,4-pentadiene-3-one C10
12 CH3 OH CH3 1,5-bis (4-hydroxy-3,5-dimethylphenyl)-1,4-pentadiene-3-one C11
13 OCH3 OH OCH3 1,5-bis (4-hydroxy-3,5-dimethoxyphenyl)-1,4-pentadiene-3-one C15
14 Cl OH Cl 1,5-bis (3,4-dichloro-4-hydroxyphenyl)-1,4-pentadiene-3-one C16
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on QSAR studies, it was clearly shown that the existence of electron 
withdrawing group inside the phenyl ring was very important for 
antimycobacterium activity [25].
The effect of anti-TB activity from C9 and C10 compound depended 
on the existence of the substituent at para and/or meta position in 
aromatic ring which could inhibit the growth of MTB [16,18]. In this 
research, the compound with chlor moiety at meta position can inhibit 
the growth of MTB, while the compound without electron withdrawing 
moiety has weaker activity as anti-TB.
This research shows the importance of aromatic ring which contains 
chlor moiety at para position as the potent anti-TB. The previous 
research showed the importance of bromo and fluoro moieties at para 
position since those two compounds could increase the activity of anti-
TB, while the electron donating moiety could decrease the activity of 
anti-TB [26]. The mechanism from anti-TB on the compound which 
has electron-withdrawing moiety is estimated has an interaction with 
protein binding on the enzyme of Inh-A which has been activated. 
The mechanism on the activated enzyme of Inh-A is really affected 
by any kinds of chemical binding and the polarity. The halogen 
compound is lipophilic since it has electronegative characteristic, so 
the halogen compound affects the activity of anti-TB [27]. The lipophilic 
characteristic is really needed since the MTB is a bacteria contained 
mycolic acid. Mycolic acid is the component which forms MTB cell wall 
that has lipophilicity. Therefore, it was needed a compound of drug 
which has lipophilicity, so it could break the biosynthesis of mycolic 
acid in the cell wall and it could cause cellular malformation which 
resulted in cell death [28].
CONCLUSION
The compound 1,5-bis(3,4-dichlorophenyl)-1,4-pentadiene-3-one(C9) 
and 1,5-bis(3-chlorophenyl)-1,4-pentadiene-3-one (C10) have 
inhibitory activity against MTB.
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